DiFabio Andrea
SEC insider (Form 3/4/5 filer). CIK 0001692506. Chief Legal Officer at Xenon Pharmaceuticals Inc. (XENE). 9 reported Form 4/5 transactions since Sep 2024; latest on Mar 13, 2026. Located in BURNABY, A1.
Companies DiFabio Andrea has filed insider reports for
- Xenon Pharmaceuticals Inc. (XENE): Officer, Chief Legal Officer
DiFabio Andrea
CIK: 0001692506
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Xenon Pharmaceuticals Inc.
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Mar 13, 2026XENE
Xenon Pharmaceuticals Inc.
SaleDirect1.3K shares at avg. $55.23$74K - Mar 12, 2026XENE
Xenon Pharmaceuticals Inc.
ExerciseDirect3.8K shares- - Mar 10, 2026XENE
Xenon Pharmaceuticals Inc.
SaleDirect2.6K shares at avg. $60.11$157K - Mar 9, 2026XENE
Xenon Pharmaceuticals Inc.
ExerciseDirect7.5K shares- - Mar 9, 2026XENE
Xenon Pharmaceuticals Inc.
AwardDirectPerformance Share Units
7.5K shares- - Jan 9, 2026XENE
Xenon Pharmaceuticals Inc.
AwardDirectShare Option (Right to Buy)
80K shares- - Jan 9, 2026XENE
Xenon Pharmaceuticals Inc.
AwardDirectRestricted Share Units
15K shares- - Mar 12, 2025XENE
Xenon Pharmaceuticals Inc.
AwardDirectRestricted Share Units
15K shares- - Mar 12, 2025XENE
Xenon Pharmaceuticals Inc.
AwardDirectShare Option (Right to Buy)
80K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 13, 2026 | XENE Xenon Pharmaceuticals Inc. | Sale | 1,342 | $55.23 | $74,112 | Direct |
| Mar 12, 2026 | XENE Xenon Pharmaceuticals Inc. | Exercise | 3,750 | - | $0 | Direct |
| Mar 10, 2026 | XENE Xenon Pharmaceuticals Inc. | Sale | 2,607 | $60.11 | $156,702 | Direct |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | Exercise | 7,500 | - | $0 | Direct |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | Award Performance Share Units | 7,500 | - | - | Direct |
| Jan 9, 2026 | XENE Xenon Pharmaceuticals Inc. | Award Share Option (Right to Buy) | 80,000 | - | - | Direct |
| Jan 9, 2026 | XENE Xenon Pharmaceuticals Inc. | Award Restricted Share Units | 15,000 | - | - | Direct |
| Mar 12, 2025 | XENE Xenon Pharmaceuticals Inc. | Award Restricted Share Units | 15,000 | - | - | Direct |
| Mar 12, 2025 | XENE Xenon Pharmaceuticals Inc. | Award Share Option (Right to Buy) | 80,000 | - | - | Direct |
1-9 of 9 transactions